^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DC-U4106

    i
    Other names: DC-U4106
    Company:
    China Pharmaceutical University, Chinese Academy of Sciences
    Drug class:
    USP8 inhibitor
    over3years
    Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. (PubMed, J Med Chem)
    In a xenograft tumor model, DC-U4106 also significantly inhibited tumor growth with minimal toxicity. Overall, our findings suggest that DC-U4106 is a promising drug candidate and targeting the USP8-ERα complex could be a new approach to treat ER-positive or drug-resistant breast cancer.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    DC-U4106